SYMDEKO

This brand name is authorized in Australia, Brazil, Canada, Israel, New Zealand

Active ingredients

The drug SYMDEKO contains a combination of these active pharmaceutical ingredients (APIs):

1 Tezacaftor UNII 8RW88Y506K - TEZACAFTOR

2 Ivacaftor UNII 1Y740ILL1Z - IVACAFTOR

Ivacaftor is a potentiator of the CFTR protein, i.e., in vitro ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations with reduced channel-open probability compared to normal CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has both low channel-open probability (gating) and reduced channel current amplitude (conductance). Read about Ivacaftor

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R07AX31		R Respiratory system → R07 Other respiratory system products → R07A Other respiratory system products → R07AX Other respiratory system products
Discover more medicines within R07AX31

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11833T, 11834W, 11854X, 11863J
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 575020070000407
Country: CA	Health Products and Food Branch	Identifier(s): 02478080
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8312, 8746
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 22304